国际泌尿系统杂志
國際泌尿繫統雜誌
국제비뇨계통잡지
INTERNATIONAL JOURNAL OF UROLOGY AND NEPHROLOGY
2011年
1期
23-26
,共4页
前列腺肿瘤%基因
前列腺腫瘤%基因
전렬선종류%기인
Prostatic Neoplasms%Genes
目的 研究白细胞分化抗原14(cluster of differentiation antigen 14,CD14)启动子区-260位点单核苷酸多态性(SNP)与影响前列腺癌预后因索的关系.方法 应用聚合酶链反应-连接酶特异检测技术(PCR-LDR)分析168例前列腺癌患者CD14基因-260位点的多态性,比较不同基因型与前列腺癌患者诊断时的前列腺癌特异性抗原(PSA)、Gleason评分和TNM临床分期的关系.结果 CD14-260 T(CT+TT)等位基因与PSA、Gleason评分和TNM临床分期均具有显著的相关性(adjusted OR=4.63,3.09,2.86;95%CI:2.87-9.28,2.12-7.33,2.21-5.31).结论 CD14-260 T(CT+TT)等位基因可能与前列腺癌预后有关,携带CD14-260 T(CT+TT)等位基因的前列腺癌患者可能预后较差.
目的 研究白細胞分化抗原14(cluster of differentiation antigen 14,CD14)啟動子區-260位點單覈苷痠多態性(SNP)與影響前列腺癌預後因索的關繫.方法 應用聚閤酶鏈反應-連接酶特異檢測技術(PCR-LDR)分析168例前列腺癌患者CD14基因-260位點的多態性,比較不同基因型與前列腺癌患者診斷時的前列腺癌特異性抗原(PSA)、Gleason評分和TNM臨床分期的關繫.結果 CD14-260 T(CT+TT)等位基因與PSA、Gleason評分和TNM臨床分期均具有顯著的相關性(adjusted OR=4.63,3.09,2.86;95%CI:2.87-9.28,2.12-7.33,2.21-5.31).結論 CD14-260 T(CT+TT)等位基因可能與前列腺癌預後有關,攜帶CD14-260 T(CT+TT)等位基因的前列腺癌患者可能預後較差.
목적 연구백세포분화항원14(cluster of differentiation antigen 14,CD14)계동자구-260위점단핵감산다태성(SNP)여영향전렬선암예후인색적관계.방법 응용취합매련반응-련접매특이검측기술(PCR-LDR)분석168례전렬선암환자CD14기인-260위점적다태성,비교불동기인형여전렬선암환자진단시적전렬선암특이성항원(PSA)、Gleason평분화TNM림상분기적관계.결과 CD14-260 T(CT+TT)등위기인여PSA、Gleason평분화TNM림상분기균구유현저적상관성(adjusted OR=4.63,3.09,2.86;95%CI:2.87-9.28,2.12-7.33,2.21-5.31).결론 CD14-260 T(CT+TT)등위기인가능여전렬선암예후유관,휴대CD14-260 T(CT+TT)등위기인적전렬선암환자가능예후교차.
Objectives To investigate the potential association between the polymorphism of -260 in the promoter of CD14 gene and prognosis factors (PSA, Gleason score and TNM clinical stage) of prostate cancer.Methods The polymorphism of CD14 -260 sites were analyzed by polymerase chain reaction - ligase detection reaction ( PCR - LDR) technique using genomic DNA isolated from peripheral blood. The association between the risk factors of prostate cancer and different genotypes was evaluated. Results The CD14 - 260T variant allele (CT+TT) was associated with higher PSA value of prostate cancer ( adjusted OR = 4.63; 95% CI = 2.87 - 9.28 ).It was also noted that the CD14 -260T variant allele was associated with higher Gleason score and advanced TNM clinical stage of prostate cancer patients ( adjusted OR = 3.09,2.86; 95% CI = 2.12 - 7.33, 2.21 - 5. 31, respectively). Conclusions The results demonstrated that the CD14 -260 C to T variant influenced the PSSA value,Gleason score and TNM clinical stage of prostate cancer. The CD14 -260T variant might be a risk factor in the prognosis of prostate cancer.